ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1978

The Effect Of Certolizumab On Lymphatic Volume and Flow In Rheumatoid Arthritis Patients With Acute Flare

Homaira Rahimi1, Vaseem Chengazi2, Gregory Dieudonne2, Edward M. Schwarz3 and Christopher T. Ritchlin4, 1Pediatrics, University of Rochester, Rochester, NY, 2Radiology, University of Rochester, Rochester, NY, 3Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lymph node, MRI, pathogenesis and rheumatoid arthritis, radiography, rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Episodic flare occurs in rheumatoid arthritis (RA) but the mechanisms of this process are not well understood. Our prior reports on MRI analysis of joints in murine arthritis models showed expanded volume and increased contrast enhancement in the popliteal node draining inflamed knees prior to arthritic flare. In the expanded node, B cells translocate to paracortical sinuses, the node suddenly collapses and there is loss of efferent lymphatic drainage and rapid onset of synovitis. Two models of flare dependent on disease duration were identified. In acute flare, joint inflammation overwhelms the lymphatics and can be effectively treated with anti-inflammatories (i.e. anti-TNF). However, mice with chronic arthritis that flare lack an efferent lymphatic pulse and are unable to normalize lymphatic function or mediate arthritic flare. To examine if similar lymph node (LN) volume and lymphatic function is altered in adult RA patients, we performed MRIs of affected joints and LN and measured lymphatic flow in RA patients with acute flare, before and after certolizumab therapy. Methods: Eight RA patients with active flare of a single wrist or knee underwent 3T pre and post contrast MRIs at baseline and 18 weeks after certolizumab. LN volumes of the popliteal or epitrochlear nodes were quantified. A subset of 3 patients underwent radiocolloid Technetium sulfur tracing (RTS) to assess lymphatic flow in the affected and unaffected extremity. RTS studies were read by a radiologist blinded to the extremity with joint flare. Results:  Of eight patients, all had improvement in disease activity score (DAS) and all six of eight with LN noted on MRI had alterations of total LN volume (Table 1.) Of those six patients, all but one had a decrease in total LN volume. Three patients underwent RTS and MRI.  Patient 1 had foot- inguinal transit time (tt) of 15min to the affected extremity that increased after treatment to 65min (normal tt is 60min), showing normalization of lymphatic flow after treatment. Patient 2 had foot -inguinal tt of 15min to the affected extremity that increased after treatment to 24min, showing deceleration in lymphatic flow. Patient 7 had long standing disease and markedly decreased lymphatic flow (hand-axillary tt >75 min, normal tt is 30min) prior to treatment that did not change with therapy; no nodes were visible on MRI pre or post treatment. Conclusion: LN volume and lymphatic flow are altered in response to anti-TNF therapy. Specifically, total LN volume decreased with certolizumab and patients with shorter disease duration appear to improve lymphatic flow, whereas patients with long-standing disease may not normalize lymphatic flow. Thus, similar to murine inflammatory arthritis, there may be an early versus chronic model of arthritic flare in which lymphatic function is a key factor and treatment response may depend on how severely lymphatic function is compromised. 

Table 1


Disclosure:

H. Rahimi,
None;

V. Chengazi,
None;

G. Dieudonne,
None;

E. M. Schwarz,
None;

C. T. Ritchlin,

Amgen, Janssen, UCB, Abbott (AbbVie), Regeneron,

5,

Amgen, Janssen, UCB,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-certolizumab-on-lymphatic-volume-and-flow-in-rheumatoid-arthritis-patients-with-acute-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology